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Summary. Degeneration f dopaminergic nigrostriatal neurons in Parkinson's 
disease results in an overactivity of excitatory glutamatergic projections from 
the subthalamic nucleus to the output nuclei of the basal ganglia resulting in 
rigidity and akinesia. In theory pharmacological blockade of these overactive 
systems hould improve parkinsonian symptomatology. The selective AMPA- 
antagonist NBQX and the competitive NMDA-antagonist CPP are not effective 
in animal models of Parkinson's disease when given alone but ameliorate par- 
kinsonian symptomatology and stimulate locomotor activity when co-admin- 
istered with a threshold ose of L-Dopa. These synergistic effects are seen in 
the MPTP-treated (1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine) common 
marmoset and the rat with unilateral 6-hydroxydopamine (6-OHDA) lesions 
of the substantia nigra. Therefore competitive NMDA and non-NMDA an- 
tagonists may offer a new therapeutic strategy for the treatment ofParkinson's 
disease. 
Keywords: L-Dopa, CPP, NMDA antagonist, NBQX, AMPA antagonist, 
MPTP, common marmosets, locomotor activity, Parkinsonism. 
Introduction 
Amino acids such as L-glutamate or L-aspartate are excitatory transmitters in 
the mammalian central nervous system (Fonnum, 1984). Their synaptic re- 
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sponses are mediated by different receptor subtypes, three of which are coupled 
to ionophores. They are activated preferentially by N-methyl-D-aspartate 
(NMDA), quisqualate (QUIS) or a-amino-3-hydroxy-5-methyl-4-isoxazolepro- 
pionate (AMPA) and kainate (KAIN), respectively. Neurodegenerative con- 
ditions such as Alzheimer's, Parkinson's and Huntington's diseases or amy- 
otrophic lateral sclerosis may be related to dysfunction of glutamatergic systems 
(Olney, 1989). This assumption is based on the observation that L-glutamate 
itself (Olney, 1969) and compounds activating major glutamate receptor sub- 
types such as NMDA, kainate and AMPA/QUIS have neurotoxic properties 
and can produce excitotoxic lesions reminiscent of human neurodegenerative 
disorders. Furthermore MPP + -induced (1-methyl-4-phenyl-pyridinium ion) de- 
generation of dopaminergic cells in the substantia nigra can be prevented by 
competitive antagonists and non-competitive antagonists of the NMDA-recep- 
tors as we have shown recently (Turski etal., 1991). Cortical excitatory glu- 
tamatergic pathways innervate the caudate nucleus, putamen and the subthal- 
amic nucleus of the basal ganglia (Carpenter, 1981). Dopaminergic projections 
arising from the substantia nigra pars compacta terminate in the caudate nucleus 
and putamen. The degeneration of dopaminergic nigrostriatal neurons in Par- 
kinson's disease results in an overactivity of the internal segment of the pallidum, 
the substantia nigra pars reticulata nd the subthalamic nucleus. The excitatory 
glutamatergic projection from the subthalamic nucleus to the pallidal output 
nuclei of the basal ganglia is overactive in experimental models of Parkinson's 
disease (Bergman et al., 1990) resulting in rigidity and akinesia. Based on these 
considerations a benefical effect of glutamate antagonists in Parkinson's disease 
has been proposed (Olney et al., 1987; Klockgether and Turski, 1989). 
Inhibition of NMDA-receptors by the non-competitive antagonist MK-801 
(( + )- 5-methyl- 10,11-dihydro- 5H-dibenzo [a,d]-cyclohepten- 5,10-imine), as 
well as by the competitive antagonist CPP (3-  ((+)-2-carboxypiperazin-4-yl)- 
propyl-l-phosphonic acid) restores locomotor activity and reduces muscular 
rigidity in catecholamine-depleted mice (Carlsson and Carlsson, 1989) and rats 
(Klockgether etal., 1990). This effect is enhanced by concomitant treatment 
with L-Dopa (Klockgether and Turski, 1990). In the unilaterally 6-OHDA 
lesioned rat MK-801 has synergistic effects on rotations induced by either L- 
Dopa or the dopamine D-1 agonist SKF 38 393 (Morelli and Di Chiara, 1990). 
The L-Dopa potentiating effects of MK-801 and CPP indicate the potential 
usefulness of NMDA-antagonists for the treatment of Parkinson's disease. This 
assumption is substantiated by the fact that memantine, a derivative of the 
antiparkinsonian gent amantadine, has NMDA-antagonistic properties (Korn- 
huber etal., 1989). However, because of the lack of potent and selective an- 
tagonists, much less is known about he role of AMPA receptors in experimental 
models of Parkinson's disease. NBQX (6-nitro-7-sulfamoyl- 
benzo[f]quinoxaline-2,3(1H,4H)-dione) s themost selective AMPA-antagonist 
described so far with an acceptable central bioavailability (Sheardown et al., 
1990). This compound thus offers the opportunity to test the hypothesis that 
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AMPA-receptors  are involved in the mediat ion of  excitatory basal ganglia 
outputs and could therefore provide a new target for the treatment of Parkin- 
son's disease. Indeed, NBQX reverses muscular igidity and akinesia in mono-  
amine-depleted rats and MPTP-treated primates (Klockgether, personal com- 
munication). The present experiments were designed to compare the antiakinetic 
properties of  NBQX with those of CPP in a rodent model of  selective dopamine 
depletion and to investigate whether the AMPA-antagonist  NBQX and the 
NMDA-antagon is t  CPP are also effective in a primate model  of Parkinson's 
disease when combined with L-Dopa. 
Material and methods 
Drugs and solutions 
The following compounds were employed: NBQX (6-Nitro-7-sulfamoyl- 
benzo[f]quinoxaline-2,3(1H,4H)-dione sodium salt; Novo Nordisk A/S), benserazide hy- 
drochloride (Hoffmann-La Roche, Switzerland), L-Dopa (L-3,4-dihydroxyphenylalanine, 
Sigma U.S.A) and CPP (3-(( 4- )-2-carboxypiperazin-4-yl)-propyl-l-phosphonic acid, Re- 
search Biochemicals, USA). CPP, L-Dopa, and benserazide were dissolved in sterile phys- 
iological saline and NBQX suspended in sterile physiological saline containing 10% (v/w) 
polyethoxylated castor oil (Cremophor, BASF, FRG). All solutions were prepared im- 
mediately before administration a d injected in a volume of 1 ml/kg body weight (monkey 
studies) or 5 ml/kg body weight (rat studies). All dosages refer to the free base. 
Rat studies 
Male Wistar rats (Dept. Animal Breeding, Schering AG) weighing 390-510g, aged 10 
months were housed in groups of 4 under standard conditions at a temperature of 22 ~ 
(4- 1 ~ using a 12 hour light-dark cycle (light on from 6.00-18.00 h). 
Stereotaxic surgery 
16 ~tg 6-OHDA HCL (Sigma, USA) dissolved in 4 gl physiological saline containing 0.02% 
ascorbic acid was injected into the left substantia nigra under pentobarbital naesthesia 
(Nembutal 50 mg/kg) 8 months prior to the experiment. The coordinates were: AP 1.9; 
L 1.8; AP -2.1 according to a stereotaxic atlas (K6nig and Klippel, 1963). 
Measurement of rotations 
Ipsiversive and contraversive rotations were registered by means of an automatic device 
consisting of 8 perspex bowls (40 cm diameter) and electro-mechanical tr nsducer systems. 
The latter registered a count (rotation) each time the animal rotated through 36 degrees. 
The number of rotations were accumulated in 10 min intervals and recorded for 120min. 
Only contraversive rotations were analysed since the number of ipsiversive rotations re- 
mained unaffected in all groups. 
Drug treatments 
2 or 6 months following injection of 6-OHDA into the left substantia nigra, 24 or 42 rats 
were randomly divided into groups of 6 animals treated with either vehicle, NBQX, ben- 
serazide followed by L-Dopa, or benserazide followed by L-dopa and NBQX. In a second 
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experiment L-Dopa and benserazide were combined with CPP. See figure legends for 
treatment schedules. 
Statistical analysis 
The means + S.E.M. were calculated for time courses and accumulated rotation counts of 
the different reatment groups. Statistical differences were calculated for rotation counts 
accumulated over 120 min by an analysis of variance followed by a Tukey test. 
Monkey studies' 
Common marmosets (Callithrix jacchus) of either sex weighing 280-420 g, aged 6-8 years 
were housed either in pairs or alone under standard conditions at a temperature of 27 ~ 
(+ 1 ~ and 50% relative humidity using a 12 hour light-dark cycle (light on from 6.00- 
18.00 h). 
MPTP-treatment 
The animals were treated with MPTP (1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine hy- 
drochloride; Schering AG) in doses of 2 mg/kg s.c. daily for up to 6 days. Since the response 
of individual animals differed markedly, variable dose regimens were applied to obtain 
comparable initial motor deficits. The cumulative doses administered ranged between 8- 
12mg/kg. Following MPTP treatment the animals recovered from acute effects over a 
period of some weeks. During the following 6 months a further gradual recovery from the 
MPTP effects was observed. Prior to behavioural testing all animals showed a reduction 
of basal locomotor activity and exhibited slower and less coordinated movements, reduced 
checking movements of the head and eye blinks, as well abnormal postures of some parts 
of the body. 
Measurment of locomotor activity 
Locomotor activity of individual animals was measured simultaneously in four aluminium 
cages (50 x 60 x 70 cm) with stainless teel grid doors (50 x 70 cm) identical to the animal's 
home cage but equipped with eight horizontally orientated sets of infrared photocells. The 
number of light beam interruptions due to the animal's movements were accumulated in
10 rain intervals and recorded for 120 rain. 
Drug treatments 
6-8 months after exposure to MPTP a group of 4 animals was treated with either vehicle, 
NBQX, benserazide followed by L-Dopa or benserazide followed by L-Dopa and NBQX. 
In a second experiment L-Dopa and benserazide were combined with CPP. The treatments 
were repeated over the following weeks allowing a one week recovery period between 
experiments. A latin square design was used for the allocation of treatments. See figure 
legends for treatment schedules. 
Statistical analysis 
The means • S.E.M. were calculated for time courses and accumulated locomotor counts 
of the different reatment groups. Statistical differences were calculated for accumulated 
locomotor counts by the non-parametric Page test for ordered alternatives using exact 
distributions. 
All animals experiments were carried out in accordance with the animal welfare guide- 
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lines and laws of Great Britain (monkey studies) and the Federal Republic of Germany 
(rat studies), respectively. 
Results 
In a first series of experiments, 24 rats were injected with the neurotoxin 6- 
OHDA into the left substantia nigra, 8 months prior to the testing of NBQX. 
All rats showed robust contraversive rotations when exposed to apomorphine 
and ipsiversive turns after amphetamine treatment consistent with unilateral 
destruction of dopamine neurones (data not shown). NBQX administered alone 
in a dose range from 0.1-12.5 mg/kg i.p. did not induce ipsiversive or contrav- 
ersive rotations in the 6-OHDA-lesioned rats. Higher doses induced sedation 
so that ipsiversive and contraversive rotations fell below the level of vehicle- 
treated controls (data not shown). A dose of 12.5 mg/kg i.p. NBQX was either 
given alone or in combination with a threshold ose of L-Dopa (25 mg/kg i.p.) 
after pretreatment with the peripheral decarboxylase inhibitor benserazide 
(100 mg/kg i.p.). L-Dopa alone induced slight rotation, whereas NBQX alone 
again reduced the response. However, the co-administration f both drugs led 
to a significant stimulation of tight nose to tail contraversive rotations (Fig. 1). 
In a second series of experiments 42 rats were injected with 6-OHDA 2 
months prior to testing of CPP. The animals were treated with vehicle of L- 
Dopa (25 mg/kg i.p.) after pretreatment with benserazide (100 mg/kg i.p.) alone 
or in combination with 5 doses of CPP (0.025-6.25 mg/kg i.p.). CPP dose- 
dependently added on to the effect of L-Dopa (Fig. 2) in a way that the rotations 
seen after 6.25 mg/kg i.p. in combination with L-Dopa were significantly dif- 
ferent from treatment with L-Dopa alone. 
Four common marmosets were rendered parkinsonian by subcutaneous 
administration of MPTP (2 mg/kg daily for up to 6 days) 6 months prior to 
testing. At the beginning of the study the animals had recovered from the acute 
effects of MPTP-treatment but still showed substantially reduced locomotor 
activity and other signs of motor impairment. In a design similar to the ex- 
periments in rats, the monkeys were treated with NBQX (6.25 mg/kg i.p.) and 
L-Dopa (20 mg/kg i.p.) plus benserazide (20 mg/kg i.p.). L-Dopa had no effect 
when given alone and NBQX reduced locomotor activity. Co-administration 
of both drugs led to amelioration of parkinsonian symptomatology followed 
by a significant stimulation of locomotor activity throughout the observation 
period, with a maximum effect 50-60 rain following administration (Fig. 3 A, 
B). The locomotor stimulation took the form of fast and well-coordinated 
movements without dyskinesia. In a second experiment all animals were treated 
with the same doses of L-Dopa and benserazide alone or in combination with 
3 doses of NBQX (0.39-6.25mg/kg). NBQX dose-dependently stimulated lo- 
comotor activity in parkinsonian monkeys (Fig. 3 C, D). 
The effects of CPP in the MPTP-model were tested in a third experiment 
with an identical design. All animals received the same doses of L-Dopa and 
benserazide alone or in combination with 3 doses of CPP (0.1-1.56 mg/kg i.p.). 
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Fig. 1. A Mean contraversive rotations (4- SEM, N = 6) accumulated in 10 min intervals 
for 120min, of male rats with 6-OHDA lesions of the left substantia nigra, following 
treatment with (a) benserazide vehicle 15 min prior to L-Dopa vehicle and NBQX vehicle 
( -  9  (b) 100 mg/kg benserazide i.p. 15 min prior to 25 mg/kg L-Dopa i.p. and vehicle 
( -  9 - ) ,  (c) vehicle 15 min prior to vehicle and 12.5 mg/kg NBQX i.p. ( -E l  - ) ,  and (d) 
100mg/kg benserazide i.p. 15 min prior to 25mg/kg L-Dopa i.p. and 12.5mg/kg NBQX 
i.p. ( - I I - ) ,  respectively. B Mean contraversive rotations (:E SEM) accumulated over 
120 min for the data shown in A. NBQX administered alone suppressed rotations whereas 
a significant stimulation was seen with the combined treatment L-Dopa plus NBQX 
(*p < 0.05, **p < 0.01, analysis of variance followed by a Tukey test) 
Fig. 2. A Mean contraversive rotations (+ SEM, N = 6) accumulated in 10min intervals 
for 120min, of male rat with 6-OHDA lesions of the left substantia nigra, following 
treatment with (a) benserazide vehicle 15 min prior to L-Dopa vehicle and CPP vehicle 
( - 9 - ), (b) 100 mg/kg benserazide i.p. 15 min prior to 25 mg/kg L-Dopa i.p. and vehicle 
( - 9 - ), (c) 100 mg/kg benserazide i.p. 15 min prior to 25 mg/kg L-Dopa i.p. and 1.56 mg/ 
kg CPP i.p. ( - [~  - ) ,  and (d) 100 mg/kg benserazide i.p. 15 min prior to 25 mg/kg L-Dopa 
i.p. and 6.25 mg/kg CPP i.p. ( - I I - ) ,  respectively. The data for the lower doses tested 
(0.025, 0.1, and 0.39 mg/kg CPP i.p.) are omitted for claritiy. The animals were pretreated 
and monitored as described in methods exept that 6-OHDA was injected 2 months prior 
to the experiment. B Mean contraversive rotations (+ SEM) accumulated over 120min 
for the data shown in A and the lower doses tested. L-Dopa administered alone induced 
rotations. A significant stimulation was seen with the combined treatment L-Dopa plus 
CPP 0.1, 0.39, 1.56, and 6.25 mg/kg i.p. The highest dose of CPP (6.25 mg/kg i.p.) was also 
significantly different from the group treated with L-Dopa alone (* p < 0.05, ** p < 0.01, 
analysis of variance followed by a Tukey test) 
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Fig. 3. A Mean locomotor activity counts (+ SEM, N = 4) accumulated in 10 min intervals 
for 120min, of MPTP-lesioned common marmosets treated with (a) benserazide vehicle 
15 min prior to L-Dopa vehicle and NBQX vehicle ( -O- ) ,  (b) 20 mg/kg benserazide i.p. 
15min prior to 20mg/kg L-Dopa i.p. and vehicle ( -  9  (c) vehicle 15min prior to 
vehicle and 6.25 mg/kg NBQX i.p. ( -  [] - ), and (d) 20 mg/kg benserazide i.p. 15 min prior 
to 20 mg/kg L-Dopa i.p. and 6.25 mg/kg NBQX i.p. ( -  [] - ) ,  respectively. Error bars for 
control and L-Dopa treatments are left out for clarity but were within the same range as 
those shown in NBQX and L-Dopa plus NBQX. B Mean locomotor activity counts 
(4- SEM) accumulated over 120min for the data shown in A. There was no difference 
between vehicle and L-Dopa treatment. However, NBQX adminstered alone reduced lo- 
comotor activity whereas a significant stimulation was seen with the combined treatment 
L-Dopa plus NBQX (p < 0.05, Page test, ordered alternative: NBQX < L-Dopa < L-Dopa 
plus NBQX). C Mean locomotor activity counts (4- SEM, N = 4) accumulated in 10min 
intervals for 120min of MPTP-lesioned common marmosets treated with (a) 20mg/kg 
benserazide i.p. 15min prior to 20mg/kg L-Dopa i.p. and vehicle ( -  9  (b) 20mg/kg 
benserazide i.p. 15 min prior to 20 mg/kg L-Dopa i.p. and 0.39 mg/kg NBQX i.p. ( -  9 - ) ,  
(c) 20 mg/kg benserazide i.p. 15 min prior to 20 mg/kg L-Dopa i.p. and 1.56 mg/kg NBQX 
i.p. ( -  [] - ), and (d) 20 mg/kg benserazide i.p. 15 min prior to 20 mg/kg L-Dopa i.p. and 
6.25 mg/kg NBQX i.p. ( - I - ) ,  respectively. Error bars for L-Dopa alone and 0.39 mg/ 
kg NBQX treatments are left out for clarity but were within the same range as those shown 
for L-Dopa plus NBQX. D Mean locomotor activity counts (4- SEM) accumulated over 
120 rain for the data shown in C. Locomotor activity was significantly stimulated by the 
combined treatment L-Dopa plus NBQX (p < 0.01, Page test, ordered alternative: L- 
Dopa < L-Dopa plus NBQX 0.39 < L-Dopa plus NBQX 1.56 < L-Dopa plus NBQX 6.25) 
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Fig. 4. A Mean locomotor activity counts (+ SEM, N = 4) accumulated in 10 min intervals 
for 120 rain of MPTP-lesioned common marmosets reated with (a) 20 mg/kg benserazide 
i.p. 15min prior to 20mg/kg L-Dopa i.p. and vehicle ( -  9  (b) 20mg/kg benserazide 
i.p. 15 min prior to 20 mg/kg L-Dopa i.p. and 0.1 mg/kg CPP i.p.. ( -  A - ) ,  (c) 20 mg/kg 
benserazide i.p. 15min prior to 20mg/kg L-Dopa i.p. and 0.39mg/kg CPP i.p. ( -N - ) ,  
and (d) 20mg/kg benserazide i.p. 15rain prior to 20mg/kg L-Dopa i.p. and 1.56mg/kg 
CPP i.p. ( -  9 - ), respectively. Error bars for L-Dopa alone and 0.1 mg/kg CPP treatments 
are left our for clarity but were within the same range as those shown for L-Dopa plus CPP. 
B Mean locomotor activity counts (• SEM) accumulated over 120 min for the data shown 
in A. Locomotor activity was significantly stimualted by the combined treatment L-Dopa 
plus CPP (p < 0.01, Page test, ordered alternative: L-Dopa < L-Dopa plus CPP 0.1 < L- 
Dopa plus CPP 0.39 < L-Dopa plus CPP 1.56). 
CPP also had synergistic effects to a threshold ose of L-Dopa in the parkin- 
sonian monkey (Fig. 4 A, B). The movements in the highest dose tested were 
qualitatively not different from normal monkeys. Dyskinesia was not observed. 
Discussion 
Injection of  6 -OHDA into the pars compacta of the substantia nigra of  rats 
selectively depletes the ipsilateral striatum from endogenous dopamine (Un- 
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gerstedt, 1968) and leads to denervation supersensitivity of postsynaptic do- 
pamine receptors. Administration of apomorphine and amphetamine induces 
a characteristic turning response in this model. Inter alia this model has been 
used to identify potential antiparkinsonian drugs. 
Administration ofMPTP to man or non-human primates (Davis et al., 1979; 
Langston et al., 1983; Burns et al., 1983) including common marmosets (Jenner 
etal., 1984)induces a parkinsonian syndrome due to the selective destruction 
of nigrostriatal neurons, associated with a substantial decrease in dopamine 
content of the caudate nucleus and putamen. The deficits in motor performance 
produced by MPTP-treatment of common marmosets respond to classical an- 
tiparkinsonian drugs such as L-Dopa in combination with a peripheral decar- 
boxylase inhibitor (Jenner et al., 1984), or dopamine receptor agonists uch as 
N-0437 (L6schmann etal., 1989). We therefore tested the effects of NBQX, 
CPP, and L-Dopa in this model. 
In two independent models of Parkinson's disease in two species the AMPA- 
antagonist NBQX had no antiparkinsonian ctivity when administered alone 
but dose-dependently potentiated the effects of a threshold ose of L-Dopa. 
Similarily the competitive NMDA-antagonist CPP had synergistic effects to L- 
Dopa in the 6-OHDA lesioned rat and the MPTP-treated monkey. These results 
are particularly important because the non-competitive NMDA-antagonist 
MK-801, although effective in rodent models of Parkinson's disease, was not 
active in the MPTP-treated common marmoset when administered alone (Close 
et al., 1990) and did not exert additive ffects to L-Dopa in another primate 
species (Crossman et al., 1989) in the same model. In contrast, CPP (Crossman, 
personal communication) and the glutamate antagonist kynurenate r verse ak- 
inesia in the MPTP-treated common marmoset following focal injection into 
the medial pallidum (Brotchie t al., 1991). Lesion of the subthalamic nucleus 
by focal injection of the neurotoxin ibotenic acid also ameliorates parkinsonian 
symptomatology in MPTP-treated green monkeys (Bergman et al., 1990). These 
results indicate that the selective reduction of glutamatergic overactivity is an 
effective strategy for the treatment of Parkinson's disease. Since the glutama- 
tergic thalamo-cortical tract seems to be underactive in Parkinson's disease 
(Bergman et al., 1990) systemic administration f glutamate antagonists should 
aggravate parkinsonian symptoms. This is probably reflected in the reduction 
of locomotor activity seen in MPTP-treated monkeys following NBQX given 
alone (Fig. 3 A, B). However, the results obtained with L-Dopa plus NBQX or 
CPP imply that stimulation of the deficient dopaminergic pathways in com- 
bination with an inhibition of the glutamatergic systems has clear synergistic 
effects on locomotor activity. 
The MPTP-treated monkey currently appears to be the best pharmacological 
model of Parkinson's disease. Our results therefore indicate the potential use- 
fulness of NBQX, and possibly other AMPA-antagonists, aswell as competitive 
NMDA-antagonists such as CPP, for the symptomatic treatment ofParkinson's 
disease when combined with L-Dopa. We predict hat such combined treatments 
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should allow a reduction of the L-Dopa dose and thus could postpone or prevent 
side effects of long-term L-Dopa treatment (Marsden and Parkes, 1976). The 
non-competitive NMDA-antagonist  MK-801 has unwanted side effects, such 
as induction of a psychosis in man (Troupin et al., 1986). Similarily, the aman- 
tadine derivative memantine, displacing [3 H]MK-801 at nanomolar concen- 
trations in binding assays (Kornhuber etal., 1991), induces pharmacotoxic 
psychosis in patients with Parkinson's disease at threshold doses required to 
elicit antiparkinsonian effects (Riederer et al., 1991). Whether non-NMDA an- 
tagonists uch as NBQX or competitive NMDA-antagonists such as CPP have 
similar side effects remains to be tested in clinical trials. 
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